{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:57:13Z","timestamp":1787061433729,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Agence Nationale de la Recherche sur le SIDA et les Maladies Infectieuses Emergentes"},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016003","name":"MIE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Target-detected (TD) results or low-level viraemia (LLV) can be observed in HIV-1 patients on ART, which regularly raises questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We describe here the impact on HIV-1 RNA quantification of switching from the COBAS AmpliPrep\/COBAS TaqMan (CAP\/CTM) to the Cobas 6800 system (C6800), based on analyses of viraemia close to the lower limit of quantification (LLoQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively selected two groups of patients: 200 individuals whose viral loads (VLs) were consistently &amp;lt;50\u2005copies\/mL with CAP\/CTM for at least 3\u2005years before switching to C6800 (group 1), and 35 other patients with confirmed LLV when C6800 was in use (group 2). In both groups, we compared several consecutive VL results performed before and after the change of quantification assay. Analyses were performed with McNemar\u2019s paired tests or Fisher\u2019s exact tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In group 1, the frequency of TD results (below or above the LLoQ) increased significantly after the switch to C6800 for patients with &amp;lt;25% of results being TD for VLs performed with CAP\/CTM (P\u200a&amp;lt;\u200a0.0001). Significantly more patients had at least one VL \u226520 or \u226550\u2005copies\/mL with C6800, in both group 1 (37.0% versus 18.5%; P\u200a&amp;lt;\u200a0.0001 and 6.5% versus 0%; P\u200a=\u200a0.0009, respectively) and group 2 (100% versus 66%; P\u200a=\u200a0.0015 and 97% versus 40%; P\u200a&amp;lt;\u200a0.0001, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>C6800 revealed residual or low-level HIV-1 RNA that was not detected with CAP\/CTM, resulting in twice as many patients being found to have a VL \u226520\u2005copies\/mL. Physicians and patients should be aware of possible differences in results between assays, and it is crucial to specify the quantitative assay used in studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkac174","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T19:08:46Z","timestamp":1654024126000},"page":"2251-2256","source":"Crossref","is-referenced-by-count":4,"title":["More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy"],"prefix":"10.1093","volume":"77","author":[{"given":"Marc","family":"Wirden","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0047-0101","authenticated-orcid":false,"given":"Romain","family":"Palich","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-0010","authenticated-orcid":false,"given":"Basma","family":"Abdi","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc Antoine","family":"Valantin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tubiana","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Schneider","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Seang","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Faycal","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Sellem","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Katlama","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Infectious Diseases , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Calvez","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, (IPLESP) , F75013, Paris , France"},{"name":"AP-HP, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Department of Virology , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"2022072817543942200_dkac174-B1","doi-asserted-by":"crossref","first-page":"104644","DOI":"10.1016\/j.jcv.2020.104644","article-title":"Evaluation of the Alinity m HIV-1 assay for the quantification of HIV-1 RNA plasma viral load in a high-throughput molecular laboratory in South Africa","volume":"132","author":"Maree","year":"2020","journal-title":"J Clin Virol"},{"key":"2022072817543942200_dkac174-B2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcv.2017.09.007","article-title":"Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep\/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load","volume":"96","author":"Wirden","year":"2017","journal-title":"J Clin Virol"},{"key":"2022072817543942200_dkac174-B3","doi-asserted-by":"crossref","first-page":"e00292-18","DOI":"10.1128\/JCM.00292-18","article-title":"Multicenter evaluation of two next-generation HIV-1 quantitation assays, Aptima Quant Dx and Cobas 6800, in comparison to the RealTime HIV-1 reference assay","volume":"56","author":"Wiesmann","year":"2018","journal-title":"J Clin Microbiol"},{"key":"2022072817543942200_dkac174-B4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12985-018-1072-x","article-title":"Performance comparison of new Veris and Xpert random access HIV-1 RNA quantification assays","volume":"15","author":"Pronier","year":"2018","journal-title":"Virol J"},{"key":"2022072817543942200_dkac174-B5","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","article-title":"Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients","volume":"58","author":"Ryscavage","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022072817543942200_dkac174-B6","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society\u2013USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2022072817543942200_dkac174-B7","article-title":"EACS Guidelines: ART \u2013 virological failure","author":"European AIDS Clinical Society"},{"key":"2022072817543942200_dkac174-B8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/QAI.0000000000002302","article-title":"Brief report: Virologic response by baseline viral load with dolutegravir plus lamivudine vs dolutegravir plus tenofovir disoproxil fumarate\/emtricitabine: pooled analysis","volume":"84","author":"Eron","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022072817543942200_dkac174-B9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dkv099","article-title":"Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice","volume":"70","author":"Wirden","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022072817543942200_dkac174-B10","doi-asserted-by":"crossref","first-page":"ofab463","DOI":"10.1093\/ofid\/ofab463","article-title":"Low-level viremia is associated with cumulative adherence to antiretroviral therapy in persons with HIV","volume":"8","author":"Castillo-Mancilla","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022072817543942200_dkac174-B11","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1172\/JCI141497","article-title":"Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists","volume":"130","author":"Siliciano","year":"2020","journal-title":"J Clin Invest"},{"key":"2022072817543942200_dkac174-B12","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/jac\/dkaa273","article-title":"Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations","volume":"75","author":"Palich","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022072817543942200_dkac174-B13","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.2147\/IDR.S332924","article-title":"Persistent low-level viremia is an independent risk factor for virologic failure: a retrospective cohort study in China","volume":"14","author":"Li","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2022072817543942200_dkac174-B14","doi-asserted-by":"crossref","first-page":"e01400-20","DOI":"10.1128\/JCM.01400-20","article-title":"Replicate Aptima assay for quantifying residual plasma viremia in individuals on antiretroviral therapy","volume":"58","author":"Bakkour","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2022072817543942200_dkac174-B15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.2018.21167","article-title":"HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable","volume":"321","author":"Eisinger","year":"2019","journal-title":"JAMA"},{"key":"2022072817543942200_dkac174-B16","article-title":"Undetectable\u200a=\u200auntransmittable","author":"UNAIDS","year":"2018"},{"key":"2022072817543942200_dkac174-B17","doi-asserted-by":"crossref","first-page":"114373","DOI":"10.1016\/j.jviromet.2021.114373","article-title":"A multi-center study comparing the analytical sensitivity and clinical concordance of three HIV-1 viral load assays","volume":"300","author":"Carmona","year":"2022","journal-title":"J Virol Methods"},{"key":"2022072817543942200_dkac174-B18","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2022072817543942200_dkac174-B19","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","article-title":"Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study","volume":"5","author":"Bavinton","year":"2018","journal-title":"Lancet HIV"},{"key":"2022072817543942200_dkac174-B20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/QAD.0b013e3283427de3","article-title":"Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy\/ml","volume":"25","author":"Ha\u00efm-Boukobza","year":"2011","journal-title":"AIDS"},{"key":"2022072817543942200_dkac174-B21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/14737159.2019.1624162","article-title":"Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations","volume":"19","author":"Aretzweiler","year":"2019","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2251\/45180548\/dkac174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2251\/45180548\/dkac174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T14:06:43Z","timestamp":1659017203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/8\/2251\/6595592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac174","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,31]]}}}